Methylene blue raises blood pressure in people whose blood pressure has fallen dangerously low, but it does not appear to push blood pressure higher in people who start with a normal reading. That distinction is crucial. Almost all of the clinical evidence on methylene blue and blood pressure comes from critically ill patients in shock, where blood vessels have relaxed so severely that standard drugs stop working. In those settings, methylene blue consistently lifts mean arterial pressure by roughly 8 to 11 mmHg and helps patients wean off other blood-pressure-supporting drugs. Outside of shock, the picture looks very different.
How Methylene Blue Affects Blood Vessels
When blood pressure crashes in certain types of shock, the culprit is often a flood of nitric oxide, a molecule that tells smooth muscle in blood vessel walls to relax. Normally, nitric oxide is helpful: it keeps vessels flexible and prevents them from clamping down too tightly. But in states like septic shock or the vasoplegic syndrome that sometimes follows heart surgery, the body produces so much nitric oxide that vessels lose their ability to constrict, and blood pressure plummets.
Methylene blue interrupts this cascade in two ways. It blocks nitric oxide synthase, the enzyme responsible for producing nitric oxide, and it also inhibits a downstream signaling molecule called soluble guanylyl cyclase. Together, those effects restore tone to blood vessel walls and make them responsive again to the body’s own pressure-raising signals and to vasopressor drugs like norepinephrine.1PubMed Central. The Mystery of Methylene Blue and Its Role in Managing Post-Cardiac Surgery Vasoplegic Shock This mechanism explains why methylene blue works best when the underlying problem is excessive vasodilation. If blood pressure is low for a different reason, such as blood loss or a failing heart muscle, methylene blue is unlikely to help and could actually cause harm by constricting vessels that need to stay open.
Evidence in Vasoplegic Shock After Heart Surgery
Vasoplegic syndrome is one of the most feared complications after cardiac surgery, especially procedures requiring cardiopulmonary bypass. The heart-lung machine can trigger a massive inflammatory response that floods the circulation with nitric oxide, and blood pressure drops even though the heart itself is pumping fine. Vasopressors like norepinephrine are the first-line treatment, but some patients simply stop responding to them.
In a cohort study of post-bypass patients who received methylene blue, mean arterial pressure rose by about 8 mmHg within two hours of administration, a statistically significant change.2PubMed Central. Methylene Blue for Postcardiopulmonary Bypass Vasoplegic Syndrome: A Cohort Study A separate study found a similar bump of roughly 11 mmHg at one hour, along with a meaningful rise in systemic vascular resistance, the measure of how tightly blood vessels are squeezing.3Journal of Cardiothoracic and Vascular Anesthesia. Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort Beyond raising the blood pressure number itself, patients in these studies gradually needed fewer vasopressors afterward, suggesting that methylene blue was not just propping up the reading temporarily but was helping the vascular system recover its own tone.4PubMed Central. Methylene Blue for Vasoplegic Syndrome after Cardiac Surgery: Early Administration Improves Survival
One thing the cardiac surgery literature emphasizes is timing. The same study that tracked early versus late administration found that giving methylene blue sooner rather than later was associated with better survival. Once organs have been starved of perfusion for hours, even a good blood pressure response may not be enough to reverse the damage already done.
Evidence in Septic Shock
Sepsis produces a similar problem to vasoplegic syndrome: a runaway inflammatory response floods the body with nitric oxide, vessels dilate, and blood pressure tanks. A systematic review and meta-analysis pooling data from multiple studies found that methylene blue increased mean arterial pressure by roughly 10 mmHg at six hours after administration and shortened the time patients needed vasopressors by about 31 hours.5PubMed Central. Methylene Blue in Septic Shock: A Systematic Review and Meta-Analysis The review rated the certainty of this evidence as low, which in research terms means the numbers are promising but could shift as larger, more rigorous trials are completed.
A small case series tracked six septic shock patients who received a loading dose of methylene blue followed by a 48-hour maintenance infusion. Their norepinephrine requirements fell progressively from the moment methylene blue started, eventually reaching zero, while mean arterial pressure stayed above 65 mmHg throughout.6PubMed Central. Effect of methylene blue on hemodynamic response in the early phase of septic shock: A case series Six patients is obviously a tiny sample, but the consistency of the response across all of them adds to the broader picture from the meta-analysis. Lactate levels, a marker of how well tissues are being perfused, also fell, which suggests the blood pressure improvement was translating into real improvement at the organ level.
What Happens When Blood Pressure Is Already Normal
Here is where the story diverges sharply from what many people expect. If you have normal blood pressure and are wondering whether methylene blue might push it higher, the available evidence suggests it will not. A study examining methylene blue in hemodialysis patients (who tend to experience blood pressure drops during treatment) measured blood pressure in healthy volunteers who served as controls. Their blood pressure remained unchanged after receiving methylene blue.7Nephrology Dialysis Transplantation. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension
Animal data tells a similar story. In an experiment using rats, intravenous methylene blue produced a brief, transient bump in blood pressure among animals that had been given endotoxin to simulate sepsis. But in the control animals that received saline instead of endotoxin, methylene blue changed neither blood pressure nor the vessels’ responsiveness to norepinephrine.8PubMed. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats Another animal study confirmed that in the absence of endotoxin, methylene blue at standard doses did not alter mean arterial pressure, even though it did raise pulmonary arterial pressure in a dose-dependent fashion.9PubMed. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock
The reason for this selectivity is the mechanism itself. When nitric oxide levels are normal, blocking its production does not make vessels dramatically constrict, because the vessels are already at a healthy baseline tone. Methylene blue corrects excessive vasodilation. It does not create vasoconstriction on top of normal physiology. This is reassuring for people who use low-dose oral methylene blue for other purposes, such as the growing (though still experimental) interest in its potential cognitive or mitochondrial benefits. However, large clinical trials in healthy people tracking blood pressure as a primary endpoint have not been conducted, so the reassurance comes mostly from the mechanistic logic and the small studies described above.
Rescue Use in Anaphylaxis and Drug Overdose
Anaphylactic shock is another scenario of catastrophic vasodilation. Epinephrine is the standard treatment, but in rare cases the blood pressure refuses to respond. Case reports and animal research suggest methylene blue can rescue these patients. In an experimental model, the combination of epinephrine and methylene blue was more effective at restoring blood pressure and preventing brain damage from poor perfusion than either drug alone.10PubMed. Methylene blue and epinephrine: a synergetic association for anaphylactic shock treatment A case report described a 21-year-old man with anaphylactic shock that did not respond to epinephrine; after methylene blue was given, his blood pressure and mental status both improved, and he was eventually taken off the ventilator.11International Journal of Medical Science and Clinical Research Studies. Role of Methylene Blue in Refractory Anaphylaxis -A Case Report
Drug overdoses can produce a similar pattern. A case report of a patient with combined beta-blocker and calcium channel blocker overdose described refractory shock that did not respond to any conventional vasopressor. A methylene blue infusion produced a dramatic blood pressure improvement, and the patient was weaned off all vasopressors without lasting organ damage.12PubMed Central. Methylene blue reverses recalcitrant shock in β-blocker and calcium channel blocker overdose These are individual case reports rather than controlled trials, but they are consistent with what the mechanism predicts: wherever nitric oxide-driven vasodilation is the bottleneck preventing blood pressure recovery, methylene blue can help break the deadlock.
Dose Matters More Than You Might Think
The standard clinical dose for hemodynamic rescue is around 1 to 2 mg/kg given intravenously, sometimes as a single bolus and sometimes followed by a continuous infusion. A retrospective study of critically ill patients compared bolus-only dosing, bolus plus continuous infusion, and continuous infusion alone. All three strategies stabilized hemodynamics, and none was clearly superior, though the bolus-only group showed the largest early drop in vasopressor requirements.13PubMed Central. Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study
Higher doses, however, can become problematic. Animal research showed that methylene blue raised systemic and pulmonary arterial pressure in a dose-dependent way up to 10 mg/kg during endotoxemia. At moderate doses, blood flow to the gut and limbs improved. But at the highest dose tested, 20 mg/kg, blood flow to the gut actually decreased while limb flow continued rising, suggesting a redistribution of blood away from the splanchnic circulation.9PubMed. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock Kidney blood flow was unaffected across all doses. The practical takeaway is that more methylene blue is not automatically better: at some point, the vasoconstriction it produces can redirect blood away from vulnerable organs rather than uniformly improving perfusion.
Pediatric Patients
Children and infants can develop refractory shock for the same reasons adults do, and the evidence on methylene blue in pediatric patients, while limited, follows a similar pattern. A systematic review of pediatric cases found that methylene blue was generally safe and raised mean arterial blood pressure across various causes of shock.14PubMed Central. Methylene blue for refractory shock in children: A systematic review and survey practice analysis In one pediatric case of vasoplegic syndrome, a dose of 1 mg/kg produced a significant blood pressure improvement that allowed the care team to start weaning vasopressors.15PubMed. The role of methylene blue in the pediatric patient with vasoplegic syndrome
A more detailed pediatric series tracked 18 individual administrations and found that mean arterial pressure improved in more than half of them at both one hour and six hours. No patients in the series developed hemolytic anemia or serotonin syndrome, two of the more feared adverse effects.16Journal of Pediatric Intensive Care. Methylene Blue Use in Pediatrics The evidence is still thin enough that methylene blue is considered a rescue therapy in children rather than a routine choice, but the safety profile so far appears acceptable when conventional vasopressors have failed.
Serotonin Syndrome Risk With Certain Medications
Methylene blue is a potent inhibitor of monoamine oxidase A (MAO-A), the enzyme that breaks down serotonin. At the concentrations reached after standard intravenous dosing, MAO-A is essentially completely blocked.17PubMed Central. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction This creates a serious interaction with serotonergic medications. If someone is taking an SSRI, an SNRI, or certain other antidepressants and then receives methylene blue, serotonin can accumulate to dangerous levels.
A case report described a patient who developed severe serotonin syndrome lasting five days after receiving methylene blue in the setting of an antidepressant overdose. The combination of methylene blue’s MAO inhibition and the excess antidepressants produced a perfect storm of serotonin excess.18PubMed Central. Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome Serotonin syndrome can itself cause blood pressure swings, both dangerously high and dangerously low, along with fever, agitation, and muscle rigidity. So while methylene blue is given to treat low blood pressure, in certain patients it could paradoxically contribute to unstable blood pressure through this entirely separate mechanism. The FDA has issued warnings about this interaction, and clinicians are supposed to screen for serotonergic medications before administering methylene blue.
This concern is especially relevant for the growing number of people experimenting with oral methylene blue purchased online. Many of those individuals may also be taking antidepressants, and the MAO-A inhibition from even low oral doses has not been thoroughly characterized in that context. If you are on any serotonergic medication and considering methylene blue, this interaction should be taken seriously.
Who Should Not Receive Methylene Blue
Beyond the serotonin issue, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency face a particular risk. G6PD deficiency is one of the most common enzyme deficiencies worldwide, affecting hundreds of millions of people, especially those of African, Mediterranean, and Southeast Asian descent. The problem is that methylene blue relies on an enzyme pathway fueled by NADPH to do its work, and G6PD is the key enzyme that generates NADPH. Without enough NADPH, the body cannot properly process methylene blue, and instead of helping, the drug can trigger a cascade of oxidative damage to red blood cells.19PubMed Central. Blue cures blue but be cautious
This is not a theoretical concern. When G6PD-deficient patients receive methylene blue, they can develop hemolytic anemia, where red blood cells break apart faster than the body can replace them. In patients who already have methemoglobinemia (often the very reason methylene blue is being considered), this creates a vicious cycle: the hemolysis worsens the methemoglobinemia, which prompts more methylene blue, which causes more hemolysis.20Blood. Favism Induced Methemoglobinemia in G6DP Deficient Patients: Case Series and Review of Literature Checking G6PD status before administering methylene blue is standard practice in emergency departments, though in a true hemodynamic crisis, clinicians sometimes have to weigh the risk of hemolysis against the risk of the patient dying from refractory shock.
How Methylene Blue Compares to Hydroxocobalamin
Hydroxocobalamin, a form of vitamin B12, has emerged as an alternative nitric oxide scavenger for vasodilatory shock. A meta-analysis comparing the two drugs in shock found that hydroxocobalamin produced a somewhat higher mean arterial pressure at one hour. However, when researchers looked at the change in blood pressure from each patient’s own baseline, there was no significant difference between the two drugs. Vasopressor requirements and mortality were also similar.21Journal of Cardiothoracic and Vascular Anesthesia. Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review with Meta Analysis for the Comparison to Methylene Blue A more recent meta-analysis focusing specifically on post-bypass vasoplegia confirmed no difference in systemic vascular resistance or mortality between the two.22PubMed. Hydroxocobalamin Versus Methylene Blue for Treatment of Vasoplegic Shock Following Cardiopulmonary Bypass: A Systematic Review and Meta-analysis
The reason hydroxocobalamin has attracted interest is partly practical. It does not carry the serotonin syndrome risk, which makes it appealing for patients on antidepressants. It also does not require the G6PD screening step. On the other hand, its evidence base is even thinner than that of methylene blue, consisting mostly of case reports and small cohorts. For now, clinicians generally reach for whichever drug they have more experience with, and methylene blue remains the more studied and more widely available option in most hospitals.
Methylene Blue for Methemoglobinemia
The most established clinical use of methylene blue has nothing to do with blood pressure at all. It is the standard antidote for methemoglobinemia, a condition in which hemoglobin is altered so it cannot carry oxygen effectively. Symptoms range from a bluish skin discoloration at mild levels to seizures and cardiovascular collapse when levels climb high enough. A case series described adult patients showing major improvement after a single dose of methylene blue, though a five-year-old child with severe symptoms responded poorly to two doses and required transfer to a specialized center.23PubMed Central. Code Blue: Life-threatening Methemoglobinemia
In the methemoglobinemia context, any blood pressure improvement is incidental. The drug is working through a completely different mechanism, acting as an electron carrier to convert the dysfunctional methemoglobin back to normal hemoglobin. But if methemoglobinemia has progressed far enough to cause cardiovascular instability, the oxygen-carrying improvement alone can stabilize blood pressure indirectly. Clinicians treating severe methemoglobinemia are focused on restoring oxygen delivery rather than on the hemodynamic effects, but the two goals often converge in practice.